|Application ||WB, IHC, IF, E|
|Calculated MW||59716 Da|
|Other Names||Glucosylceramidase, Acid beta-glucosidase, Alglucerase, Beta-glucocerebrosidase, Beta-GC, D-glucosyl-N-acylsphingosine glucohydrolase, Imiglucerase, GBA, GC, GLUC|
|Target/Specificity||GBA (NP_000148, 146 a.a. ~ 235 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||GBA Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants.
1.Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS.Bendikov-Bar I, Rapaport D, Larisch S, Horowitz MOrphanet J Rare Dis. 2014 Jun 16;9:86. doi: 10.1186/1750-1172-9-86.2.Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GMBrain. 2014 Jan 28.3.Gaucher disease paradigm: From ERAD to comorbidity.Bendikov-Bar I, Horowitz M.Hum Mutat. 2012 Oct;33(10):1398-407. doi: 10.1002/humu.22124. Epub 2012 Jun 11.4.Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.Bendikov-Bar I, Ron I, Filocamo M, Horowitz M.Blood Cells Mol Dis. 2010 Nov 22. [Epub ahead of print]5.Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, Galipeau J.Blood. 2009 Oct 8;114(15):3181-90. Epub 2009 Jul 8.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.